AzTrials
AzTrials

Gastrointestinal NeoplasmNCT06134687

Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection

A study testing Endoscopic Submucosal Dissection and Novel Rigidizing Overtube in people with Gastrointestinal Neoplasm, run by Baylor College of Medicine at 2 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this prospective, single centre, 1:1, Post Market, randomized controlled, Investigator Initiated trial, is to compare the feasibility, safety efficacy, and clinical outcomes of colonic endoscopic submucosal dissection (ESD) utilizing a novel rigidizing overtube called Pathfinder® Endoscope Overtube… Read more about this study

Who is it for?
Ages 22 years and older
Conditions the study is for
Gastrointestinal Neoplasm
What is being tested?
Endoscopic Submucosal Dissection and Novel Rigidizing Overtube
Could I receive a placebo?
No, everyone receives an active treatment
How many people
66 participants
Where
2 sitesUnited States
Study dates
4 Jun 2024to 30 May 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 22 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient is ≥ 22 years old.
  • Patients can provide written informed consent.
  • Patient is referred for ESD procedure of colonic neoplastic lesions and with one of the following criteria:
  • A - Lesions with prior resection or with scar at any size proximal to the sigmoid colon.
  • B - Granular lateral spreading tumors (GLST) more than 30mm. C - Non granular lateral spreading tumors (NGLST) more than 20 mm. D - Any suspected submucosal invasion such as Paris classification II a +II or lesions with positive non lifting sign.

Who cannot join

  • Patient refused and/or unable to provide written informed consent.
  • Patient is a pregnant or nursing woman.
  • Lesions with morphology: pedunculated type (Paris Ip, Ips).
  • Lesions located within the sigmoid colon or rectum.
  • Lesions involving appendiceal orifice or ileocecal valve

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Michael Mercado, BS contact

713-798-3606

Michael.Mercado@bcm.edu

Sara Al Yasin, BS contact

713-798-2308

Sara.AlYasin@bcm.edu

United States2 sites, 2 recruiting
  • Baylor College of Medicine

    Houston, Texas, 77030

    Mohamed O. Othman, MD, 713-798-0950, Mohamed.Othman@bcm.edu

    Recruiting
  • Baylor St. Lukes Medical Center (BSLMC)

    Houston, Texas, 77030

    Mohamed O. Othman, MD, 713-798-0950, Mohamed.Othman@bcm.edu

    Michael Mercado, 7137983606, Michael.Mercado@bcm.edu

    Recruiting

Other trials in United States

About this study

Official title: Prospective Single Centre, Post Market, Randomized Controlled Trial to Demonstrate Feasibility, Safety and Efficacy, of a Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection

The goal of this prospective, single centre, 1:1, Post Market, randomized controlled, Investigator Initiated trial, is to compare the feasibility, safety efficacy, and clinical outcomes of colonic endoscopic submucosal dissection (ESD) utilizing a novel rigidizing overtube called Pathfinder® Endoscope Overtube (Neptune Medical, Burlingame California, USA) device in comparison to conventional ESD.

The research team hypothesize that with utilizing a novel rigidizing overtube the procedure time including dissection speed and closure time will be faster due to higher scope stability and greater control over the scope tip. Subsequently, the investigators anticipate lower immediate or delayed adverse events.

Read the detailed description

Endoscopic submucosal dissection (ESD) is preferred resection method for advanced colonic polyp due to its higher rates of en bloc and R0 resection which lead to higher curative resection rate.1 In comparison to gastric ESD, colonic ESD is more challenging due to colonic unique anatomy and configuration. Tumor of size ≥ 50 mm, spreading across ≥ two folds, flexure locations have been described as strong predictors for difficulties during colonic ESD.2 Redundant colon and looping during colonoscopy may preclude successful advancement of the colonoscope and maintaining stable position for complex polyp removal.

Historically, various methods have been applied to facilitate colonoscopy and scope advancement in challenging positions and redundant colonic loops such as application of external pressure, exchange to pediatric colonoscope, torque-based reduction maneuvers, and patient repositioning. However, despite these, scope tip stabilization could potentially remain as a challenging and limiting factor for procedure progress and could lead to a longer procedure time, sedation time and perhaps lower procedure success rate. In comparison overtube-assisted colonoscopy allows for straightening of the colon to decrease angulation and loop formation.3 Several variations of overtubes have been put to use in the last few decades with comparable results such as single-balloon and double-balloon enteroscope, spiral overtube-assisted colonoscopy and double-balloon platform (DiLumenTM). DiLumen system consists of a plastic sheet fitting layer with two balloon few inches from each other in the tip of the device facilitating the scope tip stability. Most recently the efficacy of DiLumen platform were evaluated in a multicenter study including 162 patients who underwent endoscopic resection of advanced polyps.4 In this study technical success was achieved in 92% of patients without any device related adverse event. 4 In this study using an overtube resulted in faster and more efficient dissection.4 In a retrospective study of 88 polyps located within the proximal colon, ESD with assistance of traditional single balloon overtube resulted in significantly less perforation rate in polyps ≥ 40mm in the proximal colon, despite overall similar en bloc and R0 resection rates comparison to conventional ESD.5 Most recently, a novel dynamic rigidizing overtube (Pathfinder, Neptune Medical, Burlingame, Calif, USA) has been introduced to face the challenges encountered during difficult colonoscopies and to ensure scope stabilization during endoscopic mucosal resection (EMR) and ESD. The overtube material is soft and pliable on flexible state, however when the vacuum is applied the entire tube becomes 15 times stiffer.6 This unique feature of the device provides scope flexibility during colonoscope introduction and entire device stability when rigidizing system is applied.

Our team collected preliminary prospective data of 58 polyps removed by EMR (24.1%) and ESD (75.9% ) with the assistance off rigidizing overtube. Technical success (ability to complete the entire resection using the device) and clinical success (ability of endoscopic removal of polyps without changing the initial resection intent) was achieved 100% and 90% of the time, respectively. On endoscopist feedback, the rigidizing overtube was though to assist in resection in 98.3% of polyps, although the polyp was located in a somewhat/very difficult location 81% of the time. For polyps in difficult locations, the rigidizing overtube was able to maintain scope position without falling back even once, 55% of the time. This result was presented at the most recent Digestive Disease Week conference in Chicago 2023 (p1932).

As this device has been put to use recently in the United States, published literature to demonstrate its safety and efficacy in colonic ESD is lacking. The main aim of this study is to compare the feasibility, safety efficacy, and clinical outcomes of colonic endoscopic submucosal dissection (ESD) utilizing a novel rigidizing overtube called Pathfinder® Endoscope Overtube (Neptune Medical, Burlingame CA, USA) device in comparison to conventional ESD.

Being tested
Endoscopic Submucosal Dissection, Novel Rigidizing Overtube
Keywords
Endoscopic Submucosal Dissection
Medical subject headings
Gastrointestinal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Endoscopic Submucosal DissectionProcedure or surgery

    Also called ESD, Endoscopic resection

    Removal of study eligible lesions per endoscopic submucosal dissection

  • Novel Rigidizing OvertubeDevice

    Utilization of the Novel Rigidizing Overtube (Pathfinder) to aid in performing colonic endoscopic submucosal dissection

Study groups in NCT06134687
Study groupRoleWhat they receive
Treatment armExperimentalWill have endoscopic submucosal dissection performed with the use of the Pathfinder Endoscope Overtube.
Receives: Procedure: Endoscopic Submucosal Dissection; Device: Novel Rigidizing Overtube
Control armActive comparatorWill have endoscopic submucosal dissection performed through conventional means (i.e. without the Pathfinder Endoscope Overtube).
Receives: Procedure: Endoscopic Submucosal Dissection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total Procedure Time

    Total Procedure Time to perform ESD from scope in to scope out

    Measured: Day 1 (procedure day)

Secondary outcomes (8)
  1. Navigation Time

    Total time needed to reach the lesion

    Measured: Day 1 (procedure day)

  2. Technical Success

    The ability to complete the entire resection using the device without the need to change to a different tool. This will be marked as either 'yes' or 'no' on the collection report form following the procedure by the research team.

    Measured: Day 1 (procedure day)

  3. Clinical Success

    The ability of endoscopic removal of polyps without changing the initial resection intent. This will be marked as either 'yes' or 'no' on the collection report form following the procedure by the research team.

    Measured: Day 1 (procedure day)

  4. En-bloc, R0, and curative resection rates

    As collected and measured for each group

    Measured: Day 1 (procedure day)

  5. Dissection speed during colonic ESD as calculated by

    cm^2/hr

    Measured: Day 1 (procedure day)

  6. Closure time

    Time needed to close area following endoscopic resection

    Measured: Day 1 (procedure day)

  7. Sedation time

    Total time patient spent under anesthesia

    Measured: Day 1 (procedure day)

  8. User-feedback post-procedure

    Subjective assessment of the degree of difficulty reaching the lesion based on a brief questionnaire given to the endoscopist following the procedure.

    Measured: Day 1 (procedure day)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2023
  2. Study start4 Jun 2024
  3. Primary completion4 Dec 2026 (estimated)
  4. Study completion30 May 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized Controlled Trial
Masking
None (open label)
Enrolment
66 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06134687
Sponsor's protocol ID
H-53924
Status last verified
Aug 2025
First submitted
10 Nov 2023
Last updated
24 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Endoscopic Submucosal Dissection and Novel Rigidizing Overtube in people with Gastrointestinal Neoplasm, run by Baylor College of Medicine at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Michael Mercado, BS (713-798-3606, Michael.Mercado@bcm.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total Procedure Time (time frame: Day 1 (procedure day)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in